These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 34386326)
1. Polyoxypregnanes as safe, potent, and specific ABCB1-inhibitory pro-drugs to overcome multidrug resistance in cancer chemotherapy Wu X; Yin C; Ma J; Chai S; Zhang C; Yao S; Kadioglu O; Efferth T; Ye Y; To KK; Lin G Acta Pharm Sin B; 2021 Jul; 11(7):1885-1902. PubMed ID: 34386326 [TBL] [Abstract][Full Text] [Related]
2. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes. To KKW; Wu X; Yin C; Chai S; Yao S; Kadioglu O; Efferth T; Ye Y; Lin G J Ethnopharmacol; 2017 May; 203():110-119. PubMed ID: 28363522 [TBL] [Abstract][Full Text] [Related]
3. Rociletinib (CO-1686) enhanced the efficacy of chemotherapeutic agents in ABCG2-overexpressing cancer cells Zeng F; Wang F; Zheng Z; Chen Z; Wah To KK; Zhang H; Han Q; Fu L Acta Pharm Sin B; 2020 May; 10(5):799-811. PubMed ID: 32528828 [TBL] [Abstract][Full Text] [Related]
4. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters. Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420 [TBL] [Abstract][Full Text] [Related]
5. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547 [TBL] [Abstract][Full Text] [Related]
6. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847 [TBL] [Abstract][Full Text] [Related]
7. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo. Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682 [TBL] [Abstract][Full Text] [Related]
8. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo. Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876 [TBL] [Abstract][Full Text] [Related]
9. Nanoparticles of cisplatin augment drug accumulations and inhibit multidrug resistance transporters in human glioblastoma cells. Maliyakkal N; Appadath Beeran A; Udupa N Saudi Pharm J; 2021 Aug; 29(8):857-873. PubMed ID: 34408546 [TBL] [Abstract][Full Text] [Related]
10. An ester derivative of tenacigenin B from Marsdenia tenacissima (Roxb.) Wight et Arn reversed paclitaxel-induced MDR in vitro and in vivo by inhibiting both P-gp and MRP2. Wu ZL; Chen Y; Qu Z; Wu GY; He XF; Huang JW; Meng QQ; Hu YH; Shen XL; Yang RY; Hu YJ J Ethnopharmacol; 2022 Aug; 294():115353. PubMed ID: 35533911 [TBL] [Abstract][Full Text] [Related]
11. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells. Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476 [TBL] [Abstract][Full Text] [Related]
12. Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells. Ji N; Yang Y; Cai CY; Lei ZN; Wang JQ; Gupta P; Shukla S; Ambudkar SV; Kong D; Chen ZS Cancer Lett; 2019 Jan; 440-441():82-93. PubMed ID: 30315846 [TBL] [Abstract][Full Text] [Related]
13. Derivative of 5-cyano-6-phenylpyrimidin antagonizes ABCB1- and ABCG2-mediated multidrug resistance. Wang JQ; Wang B; Lei ZN; Teng QX; Li JY; Zhang W; Ji N; Cai CY; Ma LY; Liu HM; Chen ZS Eur J Pharmacol; 2019 Nov; 863():172611. PubMed ID: 31476282 [TBL] [Abstract][Full Text] [Related]
14. Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. Ji N; Yang Y; Lei ZN; Cai CY; Wang JQ; Gupta P; Xian X; Yang DH; Kong D; Chen ZS Biochem Pharmacol; 2018 Dec; 158():274-285. PubMed ID: 30431011 [TBL] [Abstract][Full Text] [Related]
15. Ceritinib Enhances the Efficacy of Substrate Chemotherapeutic Agent in Human ABCB1-Overexpressing Leukemia Cells In Vitro, In Vivo and Ex-Vivo. Yang L; Li M; Wang F; Zhen C; Luo M; Fang X; Zhang H; Zhang J; Li Q; Fu L Cell Physiol Biochem; 2018; 46(6):2487-2499. PubMed ID: 29742496 [TBL] [Abstract][Full Text] [Related]
16. CEP-33779 antagonizes ATP-binding cassette subfamily B member 1 mediated multidrug resistance by inhibiting its transport function. Tang SJ; Chen LK; Wang F; Zhang YK; Huang ZC; To KK; Wang XK; Talele TT; Chen ZS; Chen WQ; Fu LW Biochem Pharmacol; 2014 Sep; 91(2):144-56. PubMed ID: 25058526 [TBL] [Abstract][Full Text] [Related]
17. Enhancing chemosensitivity in ABCB1- and ABCG2-overexpressing cells and cancer stem-like cells by an Aurora kinase inhibitor CCT129202. Cheng C; Liu ZG; Zhang H; Xie JD; Chen XG; Zhao XQ; Wang F; Liang YJ; Chen LK; Singh S; Chen JJ; Talele TT; Chen ZS; Zhong FT; Fu LW Mol Pharm; 2012 Jul; 9(7):1971-82. PubMed ID: 22632055 [TBL] [Abstract][Full Text] [Related]
18. A Novel Synthetic Dihydroindeno[1,2-b] Indole Derivative (LS-2-3j) Reverses ABCB1- and ABCG2-Mediated Multidrug Resistance in Cancer Cells. Guo C; Liu F; Qi J; Ma J; Lin S; Zhang C; Zhang Q; Zhang H; Lu R; Li X Molecules; 2018 Dec; 23(12):. PubMed ID: 30544754 [TBL] [Abstract][Full Text] [Related]
19. Effect of abemaciclib (LY2835219) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo. Wu T; Chen Z; To KKW; Fang X; Wang F; Cheng B; Fu L Biochem Pharmacol; 2017 Jan; 124():29-42. PubMed ID: 27816545 [TBL] [Abstract][Full Text] [Related]
20. Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro. Sorf A; Hofman J; Kučera R; Staud F; Ceckova M Biochem Pharmacol; 2018 Aug; 154():10-17. PubMed ID: 29673999 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]